Regeneron's stellar success in the macular degeneration space has the stock up an incredible 218.5% for the year, putting this company at No. 14 on our list of the very best healthcare stocks of 2012.

It's the end of 2012, and that means it's time to take a look back at the year in retrospect. We'll be reading through the naughty and nice lists (we've already checked them twice), counting down the 25 best-performing stocks and the 25 worst-performing stocks in the health care sector this year.

In this segment, Motley Fool health care analyst Max Macaluso takes a look at No. 14 on the nice list, Regeneron Pharmaceuticals(NASDAQ:REGN), and how this company left investors with more than a little something extra in their stockings this year.

Author

Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo